Citations

Clear

16280 citation(s) found for "Yu, David".

AAPM Task Group No. 249.B—Essentials and guidelines for clinical medical physics residency training programs
Nye, Jonathon A. , Dugas, Joseph P., Erwin, William D. , Gierga, David P., Kaurin, D.G., Leon, Stephanie , Liu, Ho‐Ling , Lu, Zheng Feng , Magri, Alphonso, Rill, Lynn, Schubert, Leah , Schueler, Beth A. , Vergalasova, Irina , Vetter, John, Wichman, Brian, Yu, Amy S. , Leon, Stephanie M , Liu, Ho-Ling Anthony , Yu, Amy Shu-Jung , Zheng, Dandan , Zheng, Dandan

Mayo Clinic

Journal of Applied Clinical Medical Physics | May 19, 2025 | Volume: 26 | Issue: 6 | Pages: No page available

10.1002/acm2.70111 | PMID 40387591 Get It

Abstract The establishment of guidelines and curriculum standards for medical physics residency training is a critical component of setting expectations and competencies for the profession. Since the last publication of these standards, residency training has become integrated into the eligibility criteria for most medical physics certification bodies. The rapid growth of medical physics requires periodic review of the curriculum to remove outdated approaches, update established knowledge, and add emerging technologies. The goal of this document is to provide a reference standard for residency training program directors, training mentors, and residents to guide creation and/or optimization of their program's curriculum. The document is intentionally forward‐looking to capture emerging technological advances including hybrid diagnostic and therapeutic delivery systems and applications of image processing. This document is an update of the current residency training curriculum. Version history of residency training guidelines Publication Title Date 2013 Essentials and Guidelines for Clinical Medical Physics Residency Training Programs—AAPM Report No. 249 2006 Essentials and Guidelines for Hospital‐Based Medical Physics Residency Training Programs—Report No. 90 1992 Essentials and Guidelines for Hospital‐Based Medical Physics Residency Training Programs—Report No. 36 The Work Group on Periodic Review of Medical Physics Residency Training (WGMPRT) would like to acknowledge the authors of past versions of this document as they form the basis for this update. It is the sincere hope of the WGMPRT that this report will continue to be used by the medical physics community to guide training in the profession.
Immune-mediated adverse events and overall survival with tremelimumab plus durvalumab and durvalumab monotherapy in unresectable HCC: HIMALAYA phase III randomized clinical trial
Kelley, Robin Kate , Reig, María , Lim, Ho Yeong , Toni, Enrico N. De , Mody, Kabir , Crysler, Oxana , Lipatov, Oleg , Morimoto, Manabu , Archambeaud, Isabelle , Burgio, Valentina , Phuong, Le Thi Tuyet, Ko, Yoo‐Joung, Ran, Di , Makowsky, Mallory, Negro, Alejandra , De Toni, Enrico N , Reig, Maria , Lau, George , Sangro, Bruno , Cheng, Ann‐Lii , Kudo, Masatoshi , Tak, Won Young , Gasbarrini, Antonio , Tougeron, David , Tam, Vincent C. , Gong, Jun , Sukeepaisarnjaroen, Wattana , Chao, Yee , Péron, Jean‐Marie , Berres, Marie‐Luise , Ko, Yoo‐Joung, Abou‐Alfa, Ghassan K.

Mayo Clinic

Hepatology | May 19, 2025 | Volume: 83 | Issue: 3 | Pages: 484-496

10.1097/hep.0000000000001385 | PMID 40384092 Get It

Background and Aims: In the global phase III HIMALAYA study in unresectable HCC, STRIDE significantly improved overall survival (OS) versus sorafenib; durvalumab was noninferior to sorafenib. Immune checkpoint inhibitor studies have shown an association between the occurrence of immune-mediated adverse events (imAEs) and improved OS. We assessed potential associations between the occurrence of imAEs and OS, and temporal patterns of imAEs, in HIMALAYA. Approach and Results: OS in participants who did and did not experience imAEs and the frequency and timing of imAEs were assessed for STRIDE and durvalumab in the safety analysis set of HIMALAYA. imAEs occurred in 139/388 (35.8%) and 64/388 (16.5%) participants with STRIDE and durvalumab, respectively; most were low grade. OS HRs (95% CI) in participants who experienced imAEs versus those who did not were 0.73 (0.56–0.95) for STRIDE and 1.14 (0.82–1.57) for durvalumab. The 36-month OS rate (95% CI) for STRIDE was 36.2% (28.1–46.7) and 27.7% (22.4–34.2) in participants who did and did not experience imAEs, respectively. The most common imAE category with STRIDE was endocrine events (16.5%). Most imAEs occurred ≤3 months after treatment initiation. Conclusions: Participants who experienced imAEs with STRIDE had a numerical improvement in OS versus those who did not, which was not observed for durvalumab. Long-term OS with STRIDE was observed regardless of imAEs. Most imAEs were low grade, manageable, and occurred in the first 3 months after treatment initiation. Results continue to support the benefits of STRIDE in a diverse population that reflects unresectable HCC globally.
The International Classification of Vestibular Disorders: Achievements, challenges, and future directions
Kaski, Diego , Tarnutzer, Alexander A. , Carey, John P. , Cha, Yoon‐Hee , Eggers, Scott D.Z. , Furman, Joseph M. , Kim, Hyun Ah , Lempert, Thomas , López‐Escámez, José A. , Magnusson, Måns , Newman‐Toker, David E. , Seemungal, Barry M. , Berg, Raymond van de , Brevern, Michael von , Bisdorff, Alexandre , Cha, Y H , Eggers, Scott Dz, Lempert, Thomas , López-Escámez, Jose A , Magnusson, Mans , Newman-Toker, David E , Seemungal, Barry M , Staab, Jeffrey P , Agrawal, Yuri , Kim, Ji‐Soo , Staab, Jeffrey P. , Strupp, Michael Leo , Ward, Bryan Kevin

Mayo Clinic

Journal of Vestibular Research | May 17, 2025 | Volume: 35 | Issue: 3 | Pages: 105-112

10.1177/09574271251313803 | PMID 39973600 Get It

In 2007, the Bárány Society embarked on a project to establish definitions of vestibular syndromes and disorders based on best available evidence, referred to as the International Classification of Vestibular Disorders (ICVD). Since then, numerous publications providing consensus-driven diagnostic criteria for vestibular symptoms, syndromes, and disorders have been published. Here, we reflect on the rationale for developing the ICVD as well as its subsequent achievements, challenges, and outlook. In this summary of the work of the ICVD to date, the authors will focus on practical aspects to help improve the utility and applicability of these diagnostic criteria moving forward.
Integrated Molecular and Clinical Characterization of Pulmonary Large Cell Neuroendocrine Carcinoma
Chiang, Anne C. , Nassar, Amin H. , Kim, Chul , Farhat, Elias Bou , Matteson, Kelsey, Lau, Shun‐Fat , Gallegos, Jesús Antonio Ocejo , Ardeshir‐Larijani, Fatemeh , Leal, Ticiana, Alam, Sumaye, Gray, Jhanelle E. , Hicks, J. Kevin , Kaldas, David , Baena, Javier, Berjaga, María Zurera, Grohé, Christian , Leuders, Heike, Mingo, Emanuele Claudio , Pancirer, Danny, Cheung, Justin M., Lin, Jessica, Watson, Alexander, Camidge, D. Ross , Parikh, Kaushal , Aggarwal, Vanya , Ahmed, Murtaza, Zhang, Jun , Nagasaka, Misako , Awosika, Nichola, Alhamad, Khaled, Zaman, Unaiza, Gupta, Divya , Lau, Chelsea, Khan, Hina, Liauw, Justin , Brown, Tyiesha , Mosteiro, Miguel , Lopes, Gilberto , Patrick, C. , Young, Lauren K. , Aljumaily, Raid, Mirza, Haris , TAKEBE, Y., Baena, Javier , Nassar, Amin H. , Ocejo Gallegos, Jesus Antonio , Bou Farhat, Elias , Espinar, Javier Baena , Adeyelu, Tolulope Tosin , Abushukair, Hassan , Rakaee, Mehrdad , Takabe, Yamato J. , Ramalingam, Suresh S. , Alam, Sumaiya, Nana, Frank Aboubakar , Citarella, Fabrizio , Cortellini, Alessio , Das, Millie , Ellis-Caleo, Timothy John , Linehan, William Marston , Sridhar, Arthi , Crowley, Fionnuala , Marron, Thomas , Sankar, K. Nathan , Kawtharany, Hassan , Owen, Dwight H , Li, Mingjia , Pinato, David J. , Puri, Sonam , Velázquez, Ana I. , Moliner, Laura , Rocha, Pedro , Evans, Mark G. , Vanderwalde, Ari M. , Elliott, Andrew , Nieva, Jorgé , Patrick, C. , Borghaei, Hossein , Lee, Matthew , Kwiatkowski, David J. , Herbst, Roy S. , Flavell, Richard A. , Naqash, Abdul Rafeh

Mayo Clinic

No container title available | May 16, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6639680/v1 Get It

Abstract Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, aggressive lung tumor marked by significant molecular heterogeneity. In a study of 590 patients across two independent cohorts, we observed comparable overall survival across treatment regimens (chemotherapy, chemoimmunotherapy, immunotherapy) without unexpected adverse events. Genomic analysis identified distinct NSCLC-like (KEAP1, KRAS, STK11 mutations) and SCLC-like (RB1, TP53 mutations) LCNEC subtypes, with 80% aligning with SCLC transcriptional profiles. Serial sampling revealed stable mutational but shifting transcriptomic landscapes over time. NSCLC-like LCNECs showed elevated FGL-1 (a LAG-3 ligand) and SPINK1 expression, while SCLC-like subtypes expressed higher levels of DLL3. Immunofluorescence confirmed FGL-1 in NSCLC-like LCNECs, and H&E slide analyses indicated fewer tumor-infiltrating lymphocytes in LCNECs versus other lung cancers. These findings highlight LCNEC’s distinct immunogenomic profile, supporting future investigations into LAG-3, SPINK1, and DLL3-targeted therapies.
Efficacy of pharmacological therapies in reducing outflow tract obstruction in patients with obstructive hypertrophic cardiomyopathy: a systematic review and meta-analysis
Couteur, David G. Le , Wilanksy, Susan, Lester, Steven J., Ommen, Steve R. , Geske, Jeffrey B. , Arsanjani, Reza, Ayoub, Chadi , Pereyra Pietri, Milagros, Pathangey, Girish , Le Couteur, David , Geske, Jeffrey B , Ayoub, Chadi , Awad, Kamal , Pereyra, Milagros , Farina, Juan M. , Abbas, Mohammed Tiseer , Scalia, Isabel G. , Arsanjani, Reza

Mayo Clinic

European Heart Journal - Cardiovascular Pharmacotherapy | May 16, 2025 | Volume: 11 | Issue: 5 | Pages: 469-482

10.1093/ehjcvp/pvaf036 | PMID 40377024 Get It

Abstract Aims Significant advancements have been made in the management of obstructive hypertrophic cardiomyopathy (oHCM), yet the extent of left ventricular outflow tract (LVOT) gradient reduction achieved with commonly used pharmacological therapies [beta-blockers (BBs), calcium channel blockers (CCBs), disopyramide, and cardiac myosin inhibitors (CMIs)] relative to each other is still unclear. Methods and results PubMed and Scopus were searched up to September 2024. Clinical trials or observational studies that assessed the changes associated with BBs, CCBs, disopyramide, or CMIs in LVOT gradient at rest or with provocation in patients with oHCM were included. Mean changes in LVOT gradients were pooled as mean differences (MD) with 95% confidence intervals (CIs) in a random-effects model. Thirty-seven studies, with 44 arms and 1898 patients, were included in the analysis. At the therapeutic class level, pooled analysis showed that disopyramide was associated with the highest reduction in LVOT gradient at rest [MD: −43.5 (95% CI, −51.6 to −35.3)], followed by CMIs [MD: −34.8 (95% CI, −40.6 to −29.0)], BBs [MD: −20.7 (95% CI, −29.4 to −12.0)], and then CCBs [MD: −14.7 (95% CI, −23.3 to −6.1)], inter-action P < 0.01. Within CMIs, mavacamten had a higher effect than aficamten on gradient reduction; among the included BBs, metoprolol showed the highest gradient reduction, while among CCBs, verapamil was the most effective (inter-action P < 0.01). Similar results were observed for provocable LVOT gradients. Conclusion Pharmacological therapies effectively reduced LVOT gradients in oHCM patients to varying degrees, with disopyramide and CMIs showing the highest effect, followed by BBs and CCBs.
A Downward Spiral of Knee Pain and Swelling: Use of MRI to Distinguish Lyme Arthritis From Other Pediatric Arthritides
Haug, Logan, Slat, David F., Long, Jeremiah R. , Haug, Logan

Mayo Clinic

Roentgen Ray Review | May 15, 2025 | Volume: 1 | Issue: 1 | Pages: No page available

10.2214/r3j.25.01003 Get It

EEG burst dynamics as an indicator of a progressive hypoxic state
Hall, Matthew J. , Pellizzer, Giuseppe , McHail, Daniel G. , Blacker, Kara J. , Francis, David J. , Ince, Nuri F. , Hall, Matthew J.

Mayo Clinic

Journal of Neurophysiology | May 15, 2025 | Volume: 133 | Issue: 6 | Pages: 1980-1996

10.1152/jn.00430.2024 | PMID 40372949 Get It

This study reveals how EEG burst activity changes with progressive hypoxia, offering insights into its neural correlates. Increased burst features in specific frequency bands correlate strongly with physiological, such as decreasing peripheral oxygen, task performance, such as declining accuracy, and symptom measures, such as increasing report rate. Our findings characterize a neural signature with potential use for real-time EEG monitoring to enhance hypoxia detection in aviation, potentially improving flight safety.
Burden of Treatment in Patients With Heart Failure
Smith, Jamie, Killian, Jill M. , Shippee, Nathan D. , Eton, David T. , Montori, Víctor M. , Strand, Jacob J. , Dunlay, Shannon M. , Smith, Jamie L , Shippee, Nathan , Strand, Jacob J , Montori, Victor M , Dunlay, Shannon

Mayo Clinic

Journal of the American Heart Association | May 15, 2025 | Volume: 14 | Issue: 10 | Pages: No page available

10.1161/jaha.124.039695 | PMID 40371634 Get It

Background Heart failure self‐care can contribute to a high daily workload and treatment burden. The goal of this cohort study was to assess the characteristics and outcomes associated with burden of treatment (BoT). Methods Surveys comprising validated instruments to measure BoT and other constructs were mailed to patients with heart failure in Southeastern Minnesota. Participants were divided into tertiles by BoT scores. Associations of clinical variables with BoT were examined using multinomial logistic regression. Associations of BoT with mortality and hospitalizations were examined using Cox proportional hazard regression and Andersen–Gill models, respectively. Results A total of 609 participants (mean age 76.3 years, 60.3% men, 55.2% urban, 64.3% preserved ejection fraction) completed surveys. Higher BoT was associated with worse health status, more depressive symptoms, lower resilience, less social support, lower medication adherence, and worse health literacy. Mean±SD follow‐up was 14.4 (4.1) months. Estimated 1‐year mortality (8.3% [95% CI, 4.3%–12.1%], 11.0% [95% CI, 6.5%–15.2%], 16.0% [95% CI, 10.8%–21.0%]) and 1‐year mean cumulative hospitalizations (0.57 [95% CI, 0.45–0.72], 0.83 [95% CI, 0.66–1.05], 1.15 [95% CI, 0.93–1.42]) increased across patients reporting low, medium, and high BoT, respectively. Adjustment for health status eliminated any significant association of BoT with risks of death and hospitalization (adjusted hazard ratio [HR], 1.10 [95% CI, 0.58–2.07] and 1.09 [95% CI, 0.74–1.61], respectively, highest versus lowest BoT tertile). Conclusions BoT in heart failure varies by clinical and psychosocial factors. Higher BoT identifies patients at increased risk of adverse health outcomes due to their worse health status. These findings can serve as a foundation for interventions to minimize workload and improve quality of life.
The Mutational Landscape in Polycythemia Vera: Phenotype, Genotype, and Prognostic Correlates
Rana, Masooma , Iftikhar, Moazah, Jadoon, Yamna, Abdelmagid, Maymona, Viswanatha, David S., He, Rong , Reichard, Kaaren K. , Pardanani, Animesh , Gangat, Naseema , Tefferi, Ayalew , Pardanani, Animesh

Mayo Clinic

American Journal of Hematology | May 15, 2025 | Volume: 100 | Issue: 8 | Pages: 1343-1353

10.1002/ajh.27717 | PMID 40372079 Get It

ABSTRACTPolycythemia vera (PV) is invariably associated with a JAK2 mutation, with over 50% of patients harboring additional non‐JAK2 mutations. In the current study, 319 patients with PV underwent NGS at diagnosis or in chronic phase PV (Group A: N = 270, 85%) or at the time of fibrotic (Group B; N = 37, 12%) or leukemic (Group C; N = 12, 4%) transformation. Mutational frequencies involving TP53/SRSF2/IDH1/U2AF1 were significantly (p < 0.05) different between patients in the mutually exclusive Groups A (2%/4%/2%/0.4%), B (8%/0%/0%/5%), and C (50%/25%/17%/8%). Analyses on phenotype/genotype associations and prognostic impact on overall (OS), leukemia‐free (LFS), and myelofibrosis‐free (MFFS) survival were limited to Group A patients. ASXL1MUT was associated with younger age (p < 0.01), SRSF2MUT with older age and leukocytosis (p < 0.01), and TP53MUT with leukocytosis (p < 0.01). Mutation co‐segregation was apparent between ASXL1 and IDH2 (p < 0.01) or SRSF2 (p < 0.01), SRSF2 and IDH2 (p < 0.01), and TP53 and NRAS (p = 0.01). Multivariable analysis identified SRSF2MUT (p < 0.01; HR, 4.2, 1.9–9.5), IDH2MUT (p = 0.01; HR, 5.3, 1.8–15.3), ASXL1MUT (p = 0.04; HR, 2.0, 1.1–3.7), leukocyte count ≥ 15 × 109/L (p < 0.01; HR 2.0, 1.3–3.1), and advanced age (p < 0.01) as risk factors for OS. Median OS in the presence (N = 235; 87%) or absence (N = 35; 13%) of any adverse mutation (i.e., SRSF2MUT, ASXL1MUT, or IDH2MUT) was 8.8 versus 17.8 years (p = 0.01; HR 1.8, 1.1–2.9). In addition, ASXL1MUT (p = 0.02; HR, 1.6–24.9), SRSF2MUT (p = 0.06; HR, 11.9, 1.1–126.2), and advanced age (p = 0.04) were associated with inferior LFS, and SRSF2MUT (p < 0.01; HR, 24.0, 5.5–103.8) and abnormal karyotype (p < 0.01; HR 3.8, 1.6–8.9) with inferior MFFS. The number of non‐JAK2 mutations was significant in predicting outcome in univariate but not multivariable analysis. The observations from the current study highlight the prognostic significance of non‐JAK2 mutations in PV and the prospect of their inclusion in future prognostic models.
Optimal Target of Activated Clotting Time During PCI and Outcomes: The OPTIMAL-ACT Trial
Gharacholou, S. Michael , Thomas, Colleen S. , Hodge, David O. , Sabbagh, Abdallah El , Lane, Gary E. , Pollak, Peter , Pillai, Dilip, Johns, Gretchen S., Donato, Leslie J. , Singh, Mandeep , El Sabbagh, Abdallah , Pollak, Peter M , Pillai, Dilip P, Johns, Gretchen, Donato, Leslie

Mayo Clinic

Circulation: Cardiovascular Interventions | May 15, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1161/circinterventions.125.015291 | PMID 40371483 Get It